Wandercraft acquires Ekso Bionics, bringing four mobility exoskeletons under one roof

Wandercraft has acquired Ekso Bionics, bringing rehabilitation and personal mobility exoskeletons into one company. Its immediate commitment is to keep supporting all four products, an important point for clinics and people whose mobility depends on them. The deal pairs Wandercraft’s European, Middle Eastern and African reach with Ekso’s established US presence. The opportunity is broader access to robotic mobility, not simply a bigger product catalogue.

Wandercraft Watch analysis

What happened

In its announcement dated 1 October, Wandercraft said it acquired Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation. The transaction was signed and closed simultaneously, with unanimous approval from both boards. Financial terms were not disclosed.

The combined portfolio includes Atalante X and EksoNR for rehabilitation, alongside Eve and Indego Personal for eligible people with spinal cord injuries. Wandercraft says the two rehabilitation platforms currently support standing and walking at more than 700 rehabilitation centres worldwide.

The personal devices take different approaches: Eve uses hands-free, self-balancing technology, while Indego Personal is a modular wearable exoskeleton. Wandercraft intends to continue supporting both, as well as the two rehabilitation products and their existing users.

Why it matters

For a rehabilitation centre, buying an exoskeleton also means investing in training, clinical workflows and ongoing support. Keeping product-specific support while sharing clinical expertise could make the combination useful beyond the ownership change. Wandercraft says centres can now consult specialists familiar with both Atalante X and EksoNR.

For people considering a personal device, access involves more than choosing hardware. Wandercraft describes an existing team that helps users and care teams navigate documentation, reimbursement, financing and coordination with clinicians and payers. Expanding that practical machinery may matter as much as expanding the engineering team.

Our read

This is a substantial robotics deal with a clear practical test: can the combined company make suitable devices easier to obtain, train with and maintain?

The support commitment is the detail worth keeping close. Four products under one roof need not become four products squeezed into one approach. Preserving their differences gives clinicians and users options; making those options genuinely accessible is the harder work.

Clinics and prospective users should ask how training, servicing and access arrangements will work for their specific device and location. A larger company is useful only if the route to getting help becomes shorter too.

What to watch

• Whether all four products retain clear servicing, training and development plans.
• How shared clinical expertise changes support for rehabilitation centres.
• Whether the combined international network expands practical access to personal exoskeletons.
• Whether future announcements provide measurable access improvements, rather than simply a larger footprint.

Discussion spark: Should Wandercraft prioritise keeping four distinct exoskeleton platforms supported, or consolidate them to put more resources into making robotic mobility affordable and accessible?

not affiliated with or endorsed by Wandercraft